ライフサイエンスコーパス: cumulative incidence

1 versus host disease (GVHD) have measured its cumulative incidence.

2 ter SCS dosages were correlated with greater cumulative incidence.

3 l prophylaxis were associated with higher HZ cumulative incidence.

4 % to -33%) for those states with the highest cumulative incidence.

5 tervention and usual care groups (unadjusted cumulative incidence, 10.2% vs 10.6%; P = .65; adjusted

6 s ICD group (48-month Kaplan-Meier estimated cumulative incidence, 15.1% and 15.7%, respectively; haz

7 sequencing [NGS] positive), relapse (3-year cumulative incidence, 19% v 67%; P < .001) and survival

8 ted over time periods of more than 16 years (cumulative incidence, 2.2% of CRCs; 95% confidence inter

9 get lesion failure occurred in 124 patients (cumulative incidence, 22.3%) treated with ultrathin-stru

10 erage daily dosage of >=7.5 mg had a 15-year cumulative incidence (37.5%) that was 1.5-5 times greate

11 Of these, 5 reported cumulative incidence, 39 reported incidence rate and 17

12 1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%).

13 e substance use disorder at first discharge (cumulative incidence 49.4% [48.4-50.4]), and lowest in t

14 Cumulative incidence 5-years posttransplant was 24.1%.

15 1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 2

16 nths, 77 patients developed >=1 MACE (2-year cumulative incidence, 5.8%; 95% confidence interval [CI]

17 boembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major

18 age 30, when incidence rose steeply (60-year cumulative incidence, 6.6%; 95% CI, 4.1% to 9.2%), parti

19 However, the 3-year cumulative incidence (704 incident HIV infections) did n

20 The cumulative incidence (95% CI) of LEGF was 6.5% (3.0%, 14

21 onic health conditions than the 70s (20-year cumulative incidence [95% CI], 11.0% [9.7% to 12.3%] v 2

22 ith standardized incidence ratios (SIRs) and cumulative incidence analyses.

23 Outcomes were compared with cumulative incidence analysis and Cox regression.

24 Cumulative incidence and median age at onset were determ

25 ardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age

26 s without SILs at baseline, we estimated the cumulative incidence and risk factors for SILs.

27 nts without SIL at baseline we estimated the cumulative incidence and risk factors of SIL.

28 Thirty-year SMN cumulative incidence and standardized incidence ratios (

29 Within recruited ICUs, the cumulative incidence and the incidence rate of ICU-acqui

30 Next, we computed cumulative incidences and hazard rate ratios (HRRs) with

31 Next, we computed cumulative incidences and hazard rate ratios (HRRs) with

32 s was assessed in 3 ways: 1-year occurrence, cumulative incidence, and synchrony of first events.

33 gnificantly higher risk of aseptic revision (cumulative incidence at 1 year after operation, 3.0% vs

34 0.73-1.21]; P = .61) and overall mortality (cumulative incidence at 1 year after operation: 20.0% fo

35 ce interval (CI): 4.3%-10.4%) and the pooled cumulative incidence at 14.9% (95% CI: 7.7%-23.9%).

36 The cumulative incidence at 2 years of all chronic GVHD was

37 LRR cumulative incidence at 2 years: Lap 5.4%; Open 3.1% [di

38 and 1111 patients in the nonsurgical group (cumulative incidence at 8 years, 10.0% [95% CI, 7.8%-12.

39 gical group experienced a primary end point (cumulative incidence at 8-years, 30.8% [95% CI, 27.6%-34

40 Cumulative incidences at age 35 years were 1% (no chest

41 By 3 years of listing, the cumulative incidence (CI) of death or deterioration was

42 Cumulative incidence curves and Cox proportional hazard

43 ng while accounting for all predictors using cumulative incidence curves and Fine & Gray proportional

44 ng while accounting for all predictors using cumulative incidence curves and Fine and Gray proportion

45 ed the Kaplan-Meier method and nonparametric cumulative incidence curves to estimate neoplasm-free su

46 Differences in cumulative incidence curves, according to preeclampsia s

47 Accurately estimating its burden requires cumulative incidence data from longitudinal studies, whi

48 The 6-year standardized cumulative incidence difference between the unexposed an

49 Cumulative incidence differences and multivariable Cox m

50 The 5-year cumulative incidence estimates of local, distant, and co

51 83 patients developing glaucoma, the 5-year cumulative incidence following diagnosis of sustained (2

52 incisional glaucoma surgery yielded a 5-year cumulative incidence for filtering-associated endophthal

53 Whereas claims-based cumulative incidence for mortality, heart failure hospit

54 mary outcomes included hazard ratio (HR) and cumulative incidence for SCZ and BIP in the offspring.

55 ath as a competing risk, we superimposed the cumulative incidence function curve with the Kaplan-Meie

56 noncardiovascular death was assessed by the cumulative incidence function for cardiovascular death a

57 ced treatment failure and rebleeding (1-year cumulative incidence function probability of remaining f

58 for Cardio-Thoracic Surgery and reported as cumulative incidence function to account for the competi

59 priately using the KM method, instead of the cumulative incidence function.

60 Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cance

61 er estimators for survival probabilities and cumulative incidence functions accounting for competing

62 We used time-to-event analyses with cumulative incidence functions and univariate Andersen-G

63 were estimated for each treatment group with cumulative incidence functions.

64 COVID-19 cumulative incidence in states at the time of school clo

65 Three-year cumulative incidence in the PPLN-IMRT (n = 780) and PO-I

66 The cumulative incidence increased up to 20 years after prim

67 ctious individuals are more connected, local cumulative incidence is negatively correlated with popul

68 with pandemic influenza; we show that local cumulative incidence is positively correlated with popul

69 me-to-event analysis demonstrated a BIA-ALCL cumulative incidence of 0 at up to 6 years, increasing t

70 000 patients-years (95% CI 1.73-18.50), or a cumulative incidence of 0.00045% over 10 years (95% CI 0

71 nced incarceration, yielding a 1- and 5-year cumulative incidence of 1.24% and 2.59%, respectively.

72 ailure occurred in 19 patients with a 7-year cumulative incidence of 1.9% (95% CI, 1.4%-2.4%).

73 rt, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by t

74 lia (factor V Leiden carriers with a 10-year cumulative incidence of 10.9%), are associated with high

75 fty-eight CRCs were detected at anastomoses (cumulative incidence of 2.7%; 95% CI, 1.9%-3.9%).

76 71.6% of ibrutinib users, with a time to 50% cumulative incidence of 4.2 months.

77 nued well into adulthood, reaching a 60-year cumulative incidence of 6.8% (95% CI, 5.0% to 8.7%) and

78 bolism (VTE), such as older age, malignancy (cumulative incidence of 7.4% after a median of 19 months

79 The cumulative incidence of 90-day serious local complicatio

80 The cumulative incidence of a co-primary efficacy end point

81 We estimated the cumulative incidence of a composite end point of any car

82 The cumulative incidence of a post-KT infection was 36.9% at

83 The cumulative incidence of ACLF and mortality at 12 months

84 The cumulative incidence of acute GVHD grade 2 to 4 was 0.17

85 ation, the model tended to underestimate the cumulative incidence of advanced AMD for the high-risk g

86 ast 1 surveillance colonoscopy and estimated cumulative incidence of advanced neoplasia by Kaplan-Mei

87 del output of >0.5 at the baseline visit had cumulative incidence of AF 21.5% at 2 years and 52.2% at

88 The cumulative incidence of AF recurrence at 5 years was 41%

89 The cumulative incidence of all subsequent primary neoplasms

90 The 3-year cumulative incidence of any first asparaginase-associate

91 The cumulative incidence of atrioventricular valve failure a

92 The 10-year cumulative incidence of BCDF was 25.9% in the C-IMRT arm

93 The primary endpoint was cumulative incidence of BCDF.

94 The cumulative incidence of being LTFU was calculated consid

95 We also calculated the cumulative incidence of being placed on a waiting list o

96 The cumulative incidence of bipolar disorder was 24.5%, and

97 The cumulative incidence of cancer at 5, 10, and 20 years af

98 r a mean (SD) follow-up of 10.8 (7.1) years, cumulative incidence of cancer was 20% in recipients and

99 confidence interval: 56.2% to 64.2%) and the cumulative incidence of cardiac and valve-related deaths

100 The cumulative incidence of cardiac disease 30 years from di

101 The cumulative incidence of cardiovascular events and of dea

102 The cumulative incidence of cataract surgery did not depend

103 rnal mortality using Cox regression, and the cumulative incidence of cause-specific mortality within

104 eceived a diagnosis of celiac disease, for a cumulative incidence of celiac disease diagnosis of 0.06

105 The cumulative incidence of cerebrovascular events, myocardi

106 The cumulative incidence of cervical cancer was 47 cases per

107 The cumulative incidence of chronic GVHD at 24 months was 26

108 ative incidence of grade 3-4 acute GVHD, and cumulative incidence of chronic GVHD.

109 PS were associated with an increased 100-day cumulative incidence of clinically significant CMV infec

110 The cumulative incidence of CNS metastasis was 3.6% (95% CI,

111 The cumulative incidence of CNS metastasis was calculated in

112 associations were largest in states with low cumulative incidence of COVID-19 at the time of school c

113 was estimated that closing schools when the cumulative incidence of COVID-19 was in the lowest quart

114 deaths if states had closed schools when the cumulative incidence of COVID-19 was in the lowest quart

115 ty; states that closed schools earlier, when cumulative incidence of COVID-19 was low, had the larges

116 The cumulative incidence of CTGCT was estimated in the prese

117 At 10 years, the cumulative incidence of CVA was 6.3% (4.6%-8.1%) versus

118 We aimed to estimate the cumulative incidence of cyst complications and malignanc

119 The cumulative incidence of DAPT cessation was higher in HBR

120 rd arm (P = .005), with no difference in the cumulative incidence of death (P = .80).

121 r survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTF

122 The 5-year cumulative incidence of death and LTFU following treatme

123 The 10-year cumulative incidence of death as a result of lymphoma or

124 ital discharge) for these groups, as well as cumulative incidence of death by HIV status.

125 nce was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 yea

126 There was similar cumulative incidence of death over time by HIV status (P

127 The cumulative incidence of death was higher among NAS mothe

128 The cumulative incidence of death was highest for patients w

129 The primary end point was the cumulative incidence of death with heart transplantation

130 Within 10 years of first discharge, the cumulative incidence of death, self-harm, committing a v

131 The 2-year cumulative incidence of diabetes in this cohort was sign

132 statistically significant increased 10-year cumulative incidence of disease progression and definiti

133 ispanic White men, respectively, the 10-year cumulative incidence of disease progression was 59.9% vs

134 The cumulative incidence of disease-related death (CIDD) was

135 The cumulative incidence of distant failures did not differ

136 and overall mortality; however, the 10-year cumulative incidence of distant metastases was higher in

137 The cumulative incidence of embolism was not different in pa

138 During a median follow-up of 3.3 years, the cumulative incidence of embolism was significantly highe

139 The cumulative incidence of glaucoma blindness in at least 1

140 The cumulative incidence of glaucoma-induced visual impairme

141 The cumulative incidence of grade 2 to 4 acute graft-versus-

142 The cumulative incidence of grade 2 to 4 acute GVHD at day 1

143 imary objective was to determine whether the cumulative incidence of grade 2 to 4 acute GVHD could be

144 The cumulative incidence of grade 2-4 acute GVHD at day 100

145 The primary endpoint was the cumulative incidence of grade 2-4 acute GVHD at day 100

146 overall survival, progression-free survival, cumulative incidence of grade 3-4 acute GVHD, and cumula

147 The cumulative incidence of grade 3-4 pancreatitis, central

148 The cumulative incidence of HAD among survivors was 2.1% (95

149 Cumulative incidence of HCC at 5 years was 7.6% in UMHS

150 ian of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0

151 The cumulative incidence of HHV-6B plasma detection through

152 AGYW with depressive symptoms had higher cumulative incidence of HIV compared to those without (r

153 AGYW with depressive symptoms had higher cumulative incidence of HIV compared with those without

154 The primary end point was the cumulative incidence of HIV infection at 3 years.

155 The cumulative incidence of hospital-acquired pressure ulcer

156 The 1-year cumulative incidence of hospitalized infection in Medica

157 The 1-year cumulative incidence of hospitalized infection in Optum

158 The 10-year cumulative incidence of IBTR was 2.5% (n = 6) in the WBI

159 The 10-year cumulative incidence of IBTR was 4.6% (95% CI 3.7-5.7) i

160 te difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptabl

161 The estimated cumulative incidence of in-hospital mortality 90 days af

162 respiratory distress syndrome, the estimated cumulative incidence of in-hospital mortality 90 days af

163 The 1-year cumulative incidence of infection was 50.1%, 49.8%, 66.0

164 nsumption was the strongest predictor of the cumulative incidence of infections resistant to empirica

165 Five- and 10-year estimates for a cumulative incidence of invasive progression were 6.4% a

166 In this population-based cohort, the 20-year cumulative incidence of IOL dislocation needing surgical

167 Cumulative incidence of ischemic stroke at age 80 in the

168 There were no differences in the cumulative incidence of isolated bone marrow relapse, is

169 Cumulative incidence of late mortality (5 or more years

170 In 847 patients who achieved EFS24, the cumulative incidence of late relapse was 6.9% at 3 years

171 radiation to a residual primary tumor on the cumulative incidence of local progression (CILP) in pati

172 The cumulative incidence of local progression (CILP) was sig

173 compared to those without mutation (6-month cumulative incidence of local progression, 56% [range, 1

174 ree comparisons, the primary outcome was the cumulative incidence of locally acquired malaria cases.

175 The cumulative incidence of locally acquired malaria was 30.

176 The cumulative incidence of locoregional failures at 3 years

177 fractionated radiotherapy group); the 5-year cumulative incidence of locoregional recurrence was 8.3%

178 The estimated cumulative incidence of loss of response at 6 months was

179 0.73 [95% CI, 0.44 to 1.2], P = .23; 10-year cumulative incidence of LRR, 25% v 32%).

180 33 [95% CI, 0.21 to 0.52], P < .001; 10-year cumulative incidence of LRR, 6% v 21%), whereas those wi

181 Three-year cumulative incidence of LT was lower in shorter height p

182 The 30-day cumulative incidence of major hemorrhage was 0.7% (95% C

183 The cumulative incidence of medication use increased between

184 (interquartile range: 1.3 to 4.4 years), the cumulative incidence of MI or stroke was 9.8% and that o

185 The cumulative incidence of microcephaly over a median of 5.

186 (moderate, n=32; severe, n=17) with a 7-year cumulative incidence of moderate and severe SVD of 7.0%

187 ith bootstrapped confidence intervals of the cumulative incidence of mortality stratified by trajecto

188 The 2-year cumulative incidence of NC-MACE was 9% (n=103).

189 The 5-year cumulative incidence of Nd:YAG capsulotomy after catarac

190 Real-world evidence suggests that the cumulative incidence of Nd:YAG capsulotomy is significan

191 The cumulative incidence of Nd:YAG capsulotomy was estimated

192 The cumulative incidence of neutrophil engraftment at day 42

193 E demonstrated a significant increase in the cumulative incidence of NIU compared with those without

194 However, the cumulative incidence of nononcologic mortality was subst

195 The cumulative incidence of nonrelapse morality, relapse/pro

196 CI: 39.1-48.1), respectively; and the 5-year cumulative incidence of nonrelapse mortality (NRM) and r

197 Cumulative incidence of obesity 5-years posttransplant w

198 Five-year cumulative incidence of oncologic and nononcologic morta

199 The cumulative incidence of oncologic mortality was not sign

200 The cumulative incidence of pancreatic cancer is significant

201 The cumulative incidence of pancreatic cancer, high-grade dy

202 The cumulative incidence of PCR-adjusted ACPR at Day 42 was

203 The cumulative incidence of PEG-ASNase discontinuation was 1

204 were 91.8% and 75.4%, respectively, and the cumulative incidence of peri-implantitis among patients

205 t the time of PAVM embolization had a 5-year cumulative incidence of persistence of 26.3% compared wi

206 6.78%) and a predicted 1-year cumulative incidence of PJI of 3.83% (CI, 2.13% to 6.87%

207 Compared with a 2.14% 1-year cumulative incidence of PJI with abatacept, predicted in

208 The overall 90-day cumulative incidence of postoperative endophthalmitis an

209 In LOFT, cumulative incidence of primary outcomes for odanacatib

210 ed results from LOFT plus LOFT Extension for cumulative incidence of primary outcomes for odanacatib

211 nd anti-EMA) on gluten-containing diets, the cumulative incidence of progression to villous atrophy w

212 The cumulative incidence of progression to villous atrophy w

213 Secondary outcomes included lifetime cumulative incidence of prophylactic IA treatment and mo

214 p (overall P = .03 by log-rank test) and for cumulative incidence of proven or probable invasive aspe

215 The 5-month cumulative incidence of proven or probable invasive fung

216 Our main outcome measures included the cumulative incidence of RCN in ESCS, type of RCN, and mo

217 84 patients initiating chronic dialysis, the cumulative incidence of referral for transplant was 17.3

218 independent, favorable prognostic factor in cumulative incidence of relapse (4-year cumulative incid

219 respectively; P < .001), and a higher 5-year cumulative incidence of relapse (43.6%, 44.2%, 51.9%, re

220 atio 1.05 [85% CI, 0.80 to 1.38] P = .81) or cumulative incidence of relapse (CIR) (hazard ratio 0.94

221 The cumulative incidence of relapse (CIR) in patients achiev

222 zumab ozogamicin (GO) on NPM1mut TLs and the cumulative incidence of relapse (CIR) in patients with N

223 Primary end points were cumulative incidence of relapse (CIR), relapse-free surv

224 ion (P = .004), overall survival (P < .001), cumulative incidence of relapse (P = .028), disease-free

225 Two-year cumulative incidence of relapse and treatment-related mo

226 The 5-year cumulative incidence of relapse in 41 patients who under

227 e analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients with a KIR-a

228 At 24 months, the cumulative incidence of relapse was 16.3% (95% CI 8.9-23

229 At median follow up of 6.9 years, cumulative incidence of relapse was 17%.

230 rvival was 76.1% (68.6-84.5), and the 5-year cumulative incidence of relapse was 31.0% (95% CI 22.4-4

231 use of Kaplan-Meier methods, and the 5-year cumulative incidence of relapse was calculated by use of

232 The 10-year cumulative incidence of reoperation for recurrence was 1

233 The lifetime cumulative incidence of SCD at age 85 years was 9.6, 6.6

234 Cumulative incidence of SCS-associated adverse outcomes

235 Survivors treated in the 1990s had a higher cumulative incidence of severe, disabling, life-threaten

236 edian length of follow-up of 12.5 years, the cumulative incidence of SMNs by 30 years after HCT was 2

237 The cumulative incidence of SMNs increases with follow-up ti

238 od Cancer Survivor Study cohort, the 20-year cumulative incidence of SNs in NF1 childhood cancer surv

239 who completed a baseline survey, the 15-year cumulative incidence of SNs was higher among survivors w

240 ss risks (AERs; per 10 000 person-years) and cumulative incidence of specific types of subsequent pri

241 ents (CCNA), or chemotherapy alone (CA), the cumulative incidence of SPM overall was 1.33% at year 3.

242 utcomes of this 2-year interim analysis were cumulative incidence of spontaneous resolution of the ma

243 The cumulative incidence of spontaneous resolution within 2

244 by >=6 dB was 20% (95% CI 12%, 33%); 5-year cumulative incidence of sustained worsening of cup-to-di

245 The cumulative incidence of thrombosis (including arterial a

246 Cumulative incidence of time to first sustained vision g

247 Cumulative incidence of transplant decreased and cumulat

248 At 35 years after cancer diagnosis, the cumulative incidence of transplantation or being on a wa

249 isted for SPK, geographic disparities in the cumulative incidence of transplantation within 2 years d

250 e and AA race were associated with decreased cumulative incidence of transplantation.

251 tervention implementation period, and 2-year cumulative incidence of type 2 diabetes in a cohort with

252 The primary outcome was cumulative incidence of uncomplicated malaria episodes o

253 (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at

254 The cumulative incidence of VF at week 48 was 9.7% (95% CI,

255 ng the date and cause of the impairment; the cumulative incidence of visual impairment corrected for

256 07,535 patients with a new HF diagnosis, the cumulative incidence of VTE was 1.4%, 2.5%, and 10.5% at

257 lative incidence of transplant decreased and cumulative incidence of waitlist death increased as regi

258 Cumulative incidence of waitlist events (LT and dropout

259 The 5-y cumulative incidence of weaning off HPS was overestimate

260 The day 280 cumulative incidences of AAP were 7.0% for children (1.0

261 Cumulative incidences of adverse events and associated f

262 eriod of 34 months with 49,299 person-years, cumulative incidences of all-cause mortality, SH, and CV

263 ve risk reductions on the 3-year (2014-2016) cumulative incidences of all-cause pneumonia after vacci

264 Cumulative incidences of cardiac death, target vessel my

265 After adjustment for age, 5-year cumulative incidences of HCC and decompensation were sim

266 During a median of 4.6 years, the cumulative incidences of hepatitis B surface antigen and

267 The 15-year cumulative incidences of hospitalization with infection

268 Cumulative incidences of late DLBCL and indolent lymphom

269 The cumulative incidences of mutations were strongly correla

270 The 2-year cumulative incidences of nonrelapse mortality and relaps

271 Cumulative incidences of SCZ and BIP were used to inform

272 Cumulative incidences of second TC were estimated, and s

273 The cumulative incidences of transplant and waitlist death a

274 m incidence accounting for competing risks ("cumulative incidence") of neoplasms (benign and malignan

275 The cumulative incidence over 20 years was 6% in patients wi

276 d in quartiles based on state-level COVID-19 cumulative incidence per 100 000 residents at the time o

277 Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs fo

278 e probability-weighted analyses, with 1-year cumulative incidence predicted from weighted models.

279 2/34) reported at least 1 estimate of the HZ cumulative incidence (range, 0-41%).

280 (32/34) reported at least one estimate of HZ cumulative incidence (range=0%-41%).

281 ll prevalence ranged from 0.47% to 31.2% and cumulative incidence ranged from 3.7% to 27%.

282 The cumulative incidence rate difference between groups is -

283 1 years [range, 5 to 44 years]), the 15-year cumulative incidence rate of all-cause late mortality wa

284 In preterm-born children, the cumulative incidence rate of any mental and behavioral d

285 We compared the cumulative incidence rates and case-mix adjusted rates o

286 Primary safety outcomes included cumulative incidence rates for (serious) adverse events.

287 Cumulative incidence rates for CV event (atherosclerotic

288 The 5-year cumulative incidence rates of BCRL were 30.1%, 24.9%, 10

289 At 10 years, the cumulative incidence rates of CRC for individuals with n

290 he epidemic wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were

291 r in cumulative incidence of relapse (4-year cumulative incidence relapse: BM, 17% vs 36%, P = .021;

292 All-cause mortality rates, 10-year cumulative incidence risk of death, and crude and age-ad

293 Cumulative incidence, standardized mortality ratios, and

294 ntervention did not significantly change the cumulative incidence (subdistribution hazard ratio 0.91,

295 (among patients not intubated at baseline); cumulative incidences (until day 21) of prone position s

296 Cumulative incidence values of VTE were 8.07% (95% confi

297 Thirty-year SMN cumulative incidence was 3.9%, 9.0%, 10.8%, and 3.4% for

298 Overall, the 20-year crude cumulative incidence was 4.0% (95% CI, 3.5 to 4.6), with

299 Cumulative incidence was computed using competing risk m

300 Time to an event and cumulative incidence were evaluated by Kaplan-Meier anal